ClinicalTrials.gg
TerminatedNCT06341712CabOSTarUpdated Oct 29, 2026Results posted

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

A Phase 2 interventional study of Cabozantinib and Best Supportive Care (BSC) in Osteosarcoma, Osteosarcoma in Children and Osteosarcoma in Adolescents and Young Adults, sponsored by Ipsen. Terminated at 16 sites in 10 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Why this study was terminated
The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges
Updated Oct 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
5 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cabozantinib in Osteosarcoma — 5 open to participants now, 7 under way, 1 of them phase 3. cabozantinib · Osteosarcoma.

Enrollment
10th of 10
10 · median 88
Started
2024
the only one that year
Phase 2
6 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Ipsen

Among the 10 studies testing cabozantinib in Osteosarcoma, this one is the 10th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 9th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

5 of the 10 studies testing cabozantinib in Osteosarcoma are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 5 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cabozantinib in Osteosarcoma, or all of them as a file.
02

Study summary

The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.

Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid.

Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young adults.

In this study, participants will receive either cabozantinib and best supportive care or the best supportive care alone. Best supportive care will be provided at the investigator's discretion and according to institutional guidelines.

It includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including radiotherapy), etc. but does not include tumor specific therapy.

Cabozantinib will be taken by mouth (orally), as a tablet, once a day. Cabozantinib will be provided to participants who tolerate it for as long as their disease does not progress. Participants in the study receiving best supportive care alone may switch to treatment with cabozantinib and best supportive care if their disease progresses and if other eligibility criteria are met.

Participants may withdraw consent to participate at any time.

The estimated duration of the study for participants is 24 months, however a participant could remain in the study longer if demonstrating treatment benefit.

03

Conditions studied

  • Osteosarcoma
  • Osteosarcoma in Children
  • Osteosarcoma in Adolescents and Young Adults

Browse trials for

Keywords

  • Osteosarcoma
  • Cabozantinib
  • Children
  • Osteosarcoma in adolescents and young adults (AYA)
  • AYA
04

Who can participate

Ages eligible
5 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥5 and ≤30 years of age at the time of study entry.
  • or cytologically confirmed diagnosis of high-grade osteosarcoma as defined by a local pathologist
  • Participants with unresectable residual disease after standard chemotherapy treatment at diagnosis or first relapse (treated with systemic chemotherapy). A minimum of 4 cycles of systemic chemotherapy (or minimum of 2 cycles if chemotherapy was stopped early due to toxicity) must have been received.
  • Measurable residual or evaluable disease by version 1.1. Participants will be considered with evaluable disease if they have only non- as per RECIST version 1.1 criteria.
  • Absence of Progressive Disease (PD) (defined by the investigator according to RECIST version 1.1) at study entry. Note, the two most recent radiological evaluations (e.g. computerised tomography (CT) or magnetic resonance resonance imaging (MRI) scan) including the one following completion of chemotherapy should be available later to facilitate BIRC review.
  • Chemotherapy must be the last anticancer treatment received by participants before study entry and must have been completed at least 4 weeks but no longer than 2 months before randomization.
  • Participants must have recovered to Grade ≤1, except for alopecia, ototoxicity, and Grade ≤2 peripheral neuropathy, per (CTCAE) version 5.0) from the acute toxic effects of all prior anticancer therapy at study entry, unless AEs are clinically non significant and/or stable on supportive therapy, per investigator clinical judgment.
  • >6 months.
  • Performance level: participants must have a Lansky or performance status score of ≥70 corresponding to (ECOG) categories 0-1.
  • Adequate organ and marrow function.
  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.
  • Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement) (FDA 2016)
  • and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations.
  • All participants (typically ≥18 years) and/or their parents or legal guardians must sign a written and assent must be obtained from minor participants according to local guidelines.

Exclusion criteria

Exclusion Criteria :

  • Low grade osteosarcoma and periosteal osteosarcoma
  • Previous treatment with cabozantinib or another Mesenchymal-epithelial transition (MET)/hepatocyte growth factor (HGF) inhibitor (e.g., tivantinib, crizotinib).
  • Receipt of any type of small molecule kinase inhibitor (including kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before first dose of study intervention.
  • Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study intervention (or of at least 5 half-lives, whichever is shorter).
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery or major surgery e.g., removal or of brain metastasis) and stable for at least 4 weeks prior to randomization. Eligible participants must be neurologically asymptomatic and without systemic treatment at the time of randomization. Note: Participants with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures on a stable dose of anti-convulsant may be enrolled.
  • Participants who have an uncontrolled/active infection requiring systemic therapy.
  • Participants who are unable to swallow intact tablets.
  • Participants with uncontrolled, significant intercurrent or recent illness.
  • Previously identified allergy or to components of the study treatment formulations.
  • Any other active at time of first dose of study intervention or diagnosis of another malignancy within 3 years prior to first dose of study intervention that requires active treatment.
  • Pregnancy or breast-feeding.
  • Participants who in the opinion of the investigator may not be able to comply with the requirements of the study are not eligible
  • Major surgery (eg, orthopaedic surgery, removal or biopsy of brain metastasis) within 8 weeks before randomization. Complete wound healing from major surgery must have occurred 4 weeks before randomization and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before randomization. Participants with ongoing complications from prior surgery are not eligible.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Arm A: Cabozantinib+ Best supportive care (BSC)

    Participants will receive cabozantinib and BSC.

    Drug: Cabozantinib · Other: Best Supportive Care (BSC)

  • Other
    Arm B: Best supportive care (BSC)

    Participants will receive BSC alone administered per investigator's discretion and institutional guidelines.

    Other: Best Supportive Care (BSC)

Interventions

  • Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.

  • OtherBest Supportive Care (BSC)

    Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.

  • OtherBest Supportive Care (BSC)

    Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Assessed by Blinded Independent Radiology Committee (BIRC)

    PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) or the date of death due to any cause, whichever occurred first.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

Secondary outcomes

  1. Progression-free Survival Rate at 4 Months and 1 Year Assessed by Blinded Independent Radiology Committee

    PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by BIRC assessment using RECIST version 1.1 at 4 months and 1 year.

    Time frame: At 4 months and 1 year after randomization (Cycle 1 Day 1)

  2. Objective Response Rate (ORR) Assessed by Blinded Independent Radiology Committee

    ORR was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  3. Disease Control Rate (DCR) Assessed by Blinded Independent Radiology Committee

    DCR was defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  4. Progression-free Survival Assessed by Investigator

    PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to RECIST version 1.1) or the date of death due to any cause, whichever occurred first.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  5. Progression-free Survival Rate at 4 Months and 1 Year Assessed by Investigator

    PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by investigator assessment using RECIST version 1.1 at 4 months and 1 year.

    Time frame: At 4 months and 1 year after randomization (Cycle 1 Day 1)

  6. Objective Response Rate Assessed by Investigator

    ORR was defined as the percentage of participants who had achieved CR or PR determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  7. Disease Control Rate Assessed by Investigator

    DCR was defined as the percentage of participants who had achieved CR, PR, or SD determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  8. Overall Survival (OS)

    The OS was defined as the time from date of randomization to the date of death, from any cause.

    Time frame: Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

  9. Overall Survival Rate at 1 Year

    The OS rate was defined as the percentage of participants alive at 1 year.

    Time frame: At 1 year after randomization (Cycle 1 Day 1)

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (TESAEs) and Events to Monitor (ETM)

    Adverse events (AEs) were defined as any untoward medical occurrence in a clinical study participant to whom a medicinal product was administered, and which did not necessarily have a causal relationship with the treatment. SAE was defined as any medical occurrence that, at any dose, meets one or more of the criteria listed: resulted in death, was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; other medically important situations; was a suspected transmission of any infectious agent via an authorized medicinal product. ETM were AEs that may not be serious but were of special importance to a particular drug or class of drugs. TEAEs defined as any AE that started or worsened on or after the first dose of study treatment up to the earliest of death, loss to follow-up, consent withdrawal, last dose of study treatment + 30 days, or data cut-off.

    Time frame: From the first study treatment administration (Cycle 1 Day 1) up to early termination of the study, approximately 12 months

  11. Area Under the Plasma Concentration Time Curve (AUC) at Steady State of Cabozantinib

    Blood samples were planned to be collected at specified timepoints for analysis of AUC.

    Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

  12. Average Concentration (Cavg) at Steady State of Cabozantinib

    Blood samples were planned to be collected at specified timepoints for analysis of Cavg.

    Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

  13. Minimum Observed Plasma Drug Concentration (Cmin) at Steady State of Cabozantinib

    Blood samples were planned to be collected at specified timepoints for analysis of Cmin.

    Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

  14. Maximal Observed Plasma Drug Concentration (Cmax) at Steady State of Cabozantinib

    Blood samples were planned to be collected at specified timepoints for analysis of Cmax.

    Time frame: Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

  15. Acceptability and Palatability of Cabozantinib Tablets Using a Horizontal Visual Assessment Scale

    Acceptability and palatability of cabozantinib tablets in participants were planned to be assessed using a 5-point facial hedonic scale (FHS) with a correlated horizontal 100-point visual assessment scale (VAS). The face scale to assess palatability had 5 response options- very bad, bad, neither good or bad, good, very good. The VAS score ranged from 0 (least palatable) to 100 (most palatable), with higher scores indicating better palatability and acceptability.

    Time frame: Cycle 1 Day 1

  16. Change From Baseline in Score for All Paediatric Quality of Life (QoL) Inventory (PedsQL) Scales Including Generic Core Scales and Cancer Modules Throughout the Study

    The PedsQL a modular instrument was planned to measure health-related quality of life (HRQoL) in participants \<18 years of age. The PedsQL Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL disease specific modules. It assesses pain and hurt; nausea, procedural and treatment anxiety; worry, cognitive problems; perceived physical appearance, and communication. The scores for each subcategories are ranged from 0 (never) to 4 (almost always) .The total scores range from 0 to 100, with higher scores indicating better health related quality of life. Baseline was defined as the last non-missing measurement on or prior to the date of randomization.

    Time frame: From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months

  17. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Throughout the Study

    EORTC QLQ-C30 was planned to assess HRQoL, functioning, and symptoms in adult participants. It is a 30-item self-administered questionnaire for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation, and diarrhea), and 1 item on financial impact of disease. All but 2 questions have 4-point scales ranged from 0 (not at all) and 4 (very much) and 2 questions concerning global health status and QoL have 7-point scales ranged from 0 (very poor) to 7 (excellent). Total scores ranged from 0 to 100, where higher scores indicated better functioning, better HRQoL, or greater level of symptoms. Baseline was defined as last non-missing measurement on or prior to the date of randomization.

    Time frame: From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months

07

Results

Posted Oct 29, 2026
Limitations and caveats
The sponsor decided to stop study enrollment due to persistent recruitment challenges and the study was terminated. The endpoints data was not collected and analyzed due to early termination and low number of participants enrolled.

Participant flow

This Phase II, open-label, multicenter, randomized study was conducted in participants with unresectable residual osteosarcoma in 5 countries between 22 November 2024 and 27 February 2026. The sponsor decided to stop study enrollment due to persistent recruitment challenges and the study was terminated.

Participant flow — Overall Study
MilestoneCabozantinib + BSCBSC Alone
Started55
Treated53
Safety set53
Completed32
Not completed23
Withdrew: Progressive disease11
Withdrew: Other10
Withdrew: Randomized but not treated02

Outcome measures

PrimaryProgression-free Survival (PFS) Assessed by Blinded Independent Radiology Committee (BIRC)

PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) or the date of death due to any cause, whichever occurred first.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryProgression-free Survival Rate at 4 Months and 1 Year Assessed by Blinded Independent Radiology Committee

PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by BIRC assessment using RECIST version 1.1 at 4 months and 1 year.

Time frame:
At 4 months and 1 year after randomization (Cycle 1 Day 1)

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) Assessed by Blinded Independent Radiology Committee

ORR was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR) Assessed by Blinded Independent Radiology Committee

DCR was defined as the percentage of participants who had achieved CR, PR, or stable disease (SD) determined by BIRC using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryProgression-free Survival Assessed by Investigator

PFS was defined as the time from the date of randomization (Cycle 1 Day 1) to the data of first documented disease progression (according to RECIST version 1.1) or the date of death due to any cause, whichever occurred first.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryProgression-free Survival Rate at 4 Months and 1 Year Assessed by Investigator

PFS rate at 4 months and 1 year was defined as the percentage of participants who were not progressed by investigator assessment using RECIST version 1.1 at 4 months and 1 year.

Time frame:
At 4 months and 1 year after randomization (Cycle 1 Day 1)

No measurements were reported for this outcome.

SecondaryObjective Response Rate Assessed by Investigator

ORR was defined as the percentage of participants who had achieved CR or PR determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryDisease Control Rate Assessed by Investigator

DCR was defined as the percentage of participants who had achieved CR, PR, or SD determined by investigator using RECIST version 1.1. CR was defined as the disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

The OS was defined as the time from date of randomization to the date of death, from any cause.

Time frame:
Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months

No measurements were reported for this outcome.

SecondaryOverall Survival Rate at 1 Year

The OS rate was defined as the percentage of participants alive at 1 year.

Time frame:
At 1 year after randomization (Cycle 1 Day 1)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (TESAEs) and Events to Monitor (ETM)

Adverse events (AEs) were defined as any untoward medical occurrence in a clinical study participant to whom a medicinal product was administered, and which did not necessarily have a causal relationship with the treatment. SAE was defined as any medical occurrence that, at any dose, meets one or more of the criteria listed: resulted in death, was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; other medically important situations; was a suspected transmission of any infectious agent via an authorized medicinal product. ETM were AEs that may not be serious but were of special importance to a particular drug or class of drugs. TEAEs defined as any AE that started or worsened on or after the first dose of study treatment up to the earliest of death, loss to follow-up, consent withdrawal, last dose of study treatment + 30 days, or data cut-off.

Time frame:
From the first study treatment administration (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (TESAEs) and Events to Monitor (ETM)
ParticipantsCabozantinib + BSCBSC Alone
TEAEs53
TESAEs20
ETM53
SecondaryArea Under the Plasma Concentration Time Curve (AUC) at Steady State of Cabozantinib

Blood samples were planned to be collected at specified timepoints for analysis of AUC.

Time frame:
Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryAverage Concentration (Cavg) at Steady State of Cabozantinib

Blood samples were planned to be collected at specified timepoints for analysis of Cavg.

Time frame:
Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryMinimum Observed Plasma Drug Concentration (Cmin) at Steady State of Cabozantinib

Blood samples were planned to be collected at specified timepoints for analysis of Cmin.

Time frame:
Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryMaximal Observed Plasma Drug Concentration (Cmax) at Steady State of Cabozantinib

Blood samples were planned to be collected at specified timepoints for analysis of Cmax.

Time frame:
Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryAcceptability and Palatability of Cabozantinib Tablets Using a Horizontal Visual Assessment Scale

Acceptability and palatability of cabozantinib tablets in participants were planned to be assessed using a 5-point facial hedonic scale (FHS) with a correlated horizontal 100-point visual assessment scale (VAS). The face scale to assess palatability had 5 response options- very bad, bad, neither good or bad, good, very good. The VAS score ranged from 0 (least palatable) to 100 (most palatable), with higher scores indicating better palatability and acceptability.

Time frame:
Cycle 1 Day 1

No measurements were reported for this outcome.

SecondaryChange From Baseline in Score for All Paediatric Quality of Life (QoL) Inventory (PedsQL) Scales Including Generic Core Scales and Cancer Modules Throughout the Study

The PedsQL a modular instrument was planned to measure health-related quality of life (HRQoL) in participants \<18 years of age. The PedsQL Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL disease specific modules. It assesses pain and hurt; nausea, procedural and treatment anxiety; worry, cognitive problems; perceived physical appearance, and communication. The scores for each subcategories are ranged from 0 (never) to 4 (almost always) .The total scores range from 0 to 100, with higher scores indicating better health related quality of life. Baseline was defined as the last non-missing measurement on or prior to the date of randomization.

Time frame:
From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months

No measurements were reported for this outcome.

SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Throughout the Study

EORTC QLQ-C30 was planned to assess HRQoL, functioning, and symptoms in adult participants. It is a 30-item self-administered questionnaire for all cancer types. Questions are grouped into 5 multi-item functional scales (physical, role, emotional, cognitive, and social), 3 multi-item symptom scales (fatigue, pain, and nausea/vomiting), a 2-item global QoL scale, 5 single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation, and diarrhea), and 1 item on financial impact of disease. All but 2 questions have 4-point scales ranged from 0 (not at all) and 4 (very much) and 2 questions concerning global health status and QoL have 7-point scales ranged from 0 (very poor) to 7 (excellent). Total scores ranged from 0 to 100, where higher scores indicated better functioning, better HRQoL, or greater level of symptoms. Baseline was defined as last non-missing measurement on or prior to the date of randomization.

Time frame:
From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months

No measurements were reported for this outcome.

Adverse events

Collected over SAEs, other AEs and all-cause mortality data was collected from the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib + BSC1/5 (20%)2/5 (40%)5/5 (100%)
BSC Alone0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventCabozantinib + BSCBSC Alone
Influenza like illnessGeneral disorders1/50/3
ParaesthesiaNervous system disorders1/50/3
Most frequent other events
Showing 10 of 69
Most frequent other events
EventCabozantinib + BSCBSC Alone
AnaemiaBlood and lymphatic system disorders1/53/3
DiarrhoeaGastrointestinal disorders4/51/3
Aspartate aminotransferase increasedInvestigations4/50/3
ThrombocytopeniaBlood and lymphatic system disorders2/52/3
LeukopeniaBlood and lymphatic system disorders1/52/3
NauseaGastrointestinal disorders3/50/3
StomatitisGastrointestinal disorders3/50/3
Blood bilirubin increasedInvestigations3/50/3
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/50/3
FatigueGeneral disorders2/50/3

Baseline characteristics

The intent-to-treat set included all participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(years)Cabozantinib + BSCBSC AloneTotal
Mean21.6 ± 6.7418.2 ± 7.0219.9 ± 6.74
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib + BSCBSC AloneTotal
Female224
Male336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cabozantinib + BSCBSC AloneTotal
American Indian or Alaskan Native000
Asian011
Black or African American000
Native Hawaiian or Other Pacific Islander000
White448
Not Reported101
Unknown000
08

Study locations

16 sites
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • University Hospital Gent
    Ghent, Belgium
  • McGill University Health Centre - Centre for Innovative Medicine
    Québec, Canada
  • Princess Margaret cancer center
    Toronto, Canada
  • Centre Oscar Lambret
    Lille, France
  • Universitätsmedizin Mainz
    Mainz, Germany
  • Dr. von Haunerschen Kinderspital
    München, Germany
  • Ospedale Ortopedico Rizzoli di Bologna
    Bologna, Italy
  • AOU Città della Salute e della Scienza di Torino
    Piemonte, Italy
  • Amsterdam UMC - Locatie AMC
    Amsterdam, Netherlands
  • Instytut Matki i Dziecka
    Warsaw, Poland
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, Spain
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2026, 15 months.

Results were first posted in Oct 2026, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Apr 2, 2024
StartActual
Nov 22, 2024
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression-free Survival (PFS) assessedAssessed by Blinded Independent Radiology Committee (BIRC)Time frame: From randomization until disease progression or death from any cause, whichever occurs first (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
Oct 29, 2026
Documents
Secondary outcomes
17 edited
What changed in the outcomes
  • EditedProgression-free survival (PFS) rate assessedSurvival Rate at 4 Months and 1 Year Assessed by BIRCBlinded Independent Radiology CommitteeTime frame: 4 months and 1 year after randomization. → At 4 months and 1 year after randomization (Cycle 1 Day 1)
  • EditedObjective response rateResponse Rate (ORR) assessedAssessed by BIRCBlinded Independent Radiology CommitteeTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedDisease control rateControl Rate (DCR) assessedAssessed by BIRCBlinded Independent Radiology CommitteeTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedPFS assessedProgression-free Survival Assessed by investigatorInvestigatorTime frame: From randomization until disease progression or death from any cause, whichever occurs first (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedPFS rate assessedObjective Response Rate Assessed by investigatorInvestigatorTime frame: At 4 months and 1 year after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedORR assessedDisease Control Rate Assessed by investigatorInvestigatorTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedOverall survivalSurvival (OS)Time frame: From randomization until death or last contact (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
  • EditedOverall Survival Rate at 1-year overall survival rate YearTime frame: At 1 year after randomization. → At 1 year after randomization (Cycle 1 Day 1)
  • EditedPercentageNumber of participants withParticipants With Treatment -Emergent Adverse EventEvents (TEAEs) and Serious Treatment-Emergent Adverse Events of Special Interest(TESAEs) and Events to Monitor (AESIsETM).Time frame: From screening to 30 days after last dose. → From the first study treatment administration (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
  • EditedArea Under the Plasma Concentration Time Curve (AUC) at steady state.Steady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
  • EditedAverage concentrationConcentration (Cavg) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
  • EditedMinimum concentrationObserved Plasma Drug Concentration (Cmin) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
  • EditedMaximal concentrationObserved Plasma Drug Concentration (Cmax) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
  • EditedAcceptability and palatability in children and adolescents assessed usingPalatability of Cabozantinib Tablets Using a horizontal visual assessment scale.Horizontal Visual Assessment ScaleTime frame: Day of first dose. → Cycle 1 Day 1
  • EditedChange from baselineFrom Baseline in scoreScore for allAll Paediatric Quality of Life (QoL) Inventory (PedsQL) Scales includingIncluding Generic Core Scales and Cancer Modules. Throughout the StudyTime frame: From screening to 30 days after last dose. → From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
  • EditedChange from baselineFrom Baseline in European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) (EORTC QLQ-C30) for adult participantsThroughout the StudyTime frame: From screening to 30 days after last dose. → From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
  • ChangedBefore DCR assessed by investigatorNow Progression-free Survival Rate at 4 Months and 1 Year Assessed by InvestigatorTime frame: Approximately 34 months after randomization. → At 4 months and 1 year after randomization (Cycle 1 Day 1)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression-free Survival (PFS) assessedAssessed by Blinded Independent Radiology Committee (BIRC)Time frame: From randomization until disease progression or death from any cause, whichever occurs first (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    Secondary outcomes 17 edited
    What changed in the outcomes
    • EditedProgression-free survival (PFS) rate assessedSurvival Rate at 4 Months and 1 Year Assessed by BIRCBlinded Independent Radiology CommitteeTime frame: 4 months and 1 year after randomization. → At 4 months and 1 year after randomization (Cycle 1 Day 1)
    • EditedObjective response rateResponse Rate (ORR) assessedAssessed by BIRCBlinded Independent Radiology CommitteeTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedDisease control rateControl Rate (DCR) assessedAssessed by BIRCBlinded Independent Radiology CommitteeTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedPFS assessedProgression-free Survival Assessed by investigatorInvestigatorTime frame: From randomization until disease progression or death from any cause, whichever occurs first (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedPFS rate assessedObjective Response Rate Assessed by investigatorInvestigatorTime frame: At 4 months and 1 year after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedORR assessedDisease Control Rate Assessed by investigatorInvestigatorTime frame: Approximately 34 months after randomization. → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedOverall survivalSurvival (OS)Time frame: From randomization until death or last contact (approximately 34 months). → Baseline (Cycle 1 Day 1) and every 8 weeks during the treatment period and then every 3 months during the follow up period until disease progression or death from any cause, whichever occurs first. The maximum study duration was approximately 12 months
    • EditedOverall Survival Rate at 1-year overall survival rate YearTime frame: At 1 year after randomization. → At 1 year after randomization (Cycle 1 Day 1)
    • EditedPercentageNumber of participants withParticipants With Treatment -Emergent Adverse EventEvents (TEAEs) and Serious Treatment-Emergent Adverse Events of Special Interest(TESAEs) and Events to Monitor (AESIsETM).Time frame: From screening to 30 days after last dose. → From the first study treatment administration (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
    • EditedArea Under the Plasma Concentration Time Curve (AUC) at steady state.Steady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
    • EditedAverage concentrationConcentration (Cavg) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
    • EditedMinimum concentrationObserved Plasma Drug Concentration (Cmin) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
    • EditedMaximal concentrationObserved Plasma Drug Concentration (Cmax) at steady stateSteady State of CabozantinibTime frame: At Day 1 of week 1 and Day 1 of week 5. → Pre-dose and 4 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1
    • EditedAcceptability and palatability in children and adolescents assessed usingPalatability of Cabozantinib Tablets Using a horizontal visual assessment scale.Horizontal Visual Assessment ScaleTime frame: Day of first dose. → Cycle 1 Day 1
    • EditedChange from baselineFrom Baseline in scoreScore for allAll Paediatric Quality of Life (QoL) Inventory (PedsQL) Scales includingIncluding Generic Core Scales and Cancer Modules. Throughout the StudyTime frame: From screening to 30 days after last dose. → From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
    • EditedChange from baselineFrom Baseline in European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) (EORTC QLQ-C30) for adult participantsThroughout the StudyTime frame: From screening to 30 days after last dose. → From the first dose of study treatment (Cycle 1 Day 1) up to early termination of the study, approximately 12 months
    • ChangedBefore DCR assessed by investigatorNow Progression-free Survival Rate at 4 Months and 1 Year Assessed by InvestigatorTime frame: Approximately 34 months after randomization. → At 4 months and 1 year after randomization (Cycle 1 Day 1)
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06341712
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Nov 22, 2024
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion